Monrovia, CA – According to filings with the U.S. Securities and Exchange Commission, CytoImmune Therapeutics is raising $100,343,439.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Aleksey Krylov played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About CytoImmune Therapeutics
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to utilize the power of the patients own immune system to eliminate cancer cells. We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market. Currently we are developing our proprietary Chimeric Antigen Receptor (CAR) engineered NK cells (CAR-NK) technology, which we licensed from the laboratories of Drs. Michael Caligiuri and Jianhua Yu at the City of Hope National Medical Center (COH).

To learn more about CytoImmune Therapeutics, visit http://www.cytoimmune.com/

Contact:
Aleksey Krylov, Chief Financial Officer
469-222-2350
https://www.linkedin.com/in/aleksey-krylov/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved